Antonio Germane Alves

Jun 5, 2024 | nature.com | Bruna Costa |Marta Estrada |José Azevedo |Vanda Póvoa |Marcia Fontes |Antonio Germane Alves | +4 more

AbstractCancer patients often undergo rounds of trial-and-error to find the most effective treatment because there is no test in the clinical practice for predicting therapy response. Here, we conduct a clinical study to validate the zebrafish patient-derived xenograft model (zAvatar) as a fast predictive platform for personalized treatment in colorectal cancer.